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Abstract
The aim of this work was to study the bioavailability of fatty acids (FA), focusing on n-3 long-chain (LC) PUFA, carried by different molecular lipid
species, that is, phospholipids (PL) or TAG, with three formulations based on fish oils or marine PL, providing a similar n-3 LC PUFA amount. The
digestive lipolysis was first assessed using an in vitro enzymatic model. Then, intestinal absorption and enterocyte metabolism were investigated
in vivo, onmaleWistar rats through lymph lipid analysis. The in vitro results showed that the release ofn-3 LCPUFA from lipolysiswas increasedby
48 % when FA were provided as PL rather than TAG. The in vivo results demonstrated that EPA and DHA from both TAG and PL were similarly
absorbed and incorporated into lymph lipids. However, DHA was mainly distributed at the sn-1/3 positions of lymph TAG when provided as
marine PL, whereas it was equally distributed at the three positions with marine TAG. On the whole, even if the molecular lipid species of
n-3 LC PUFA did not greatly modify the in vivo digestion and absorption steps, it modulated the rearrangement of DHA on the glyceride positions
of the lymph TAG, which may further impact the DHA metabolic fate and tissue accretion. Consequently, the present study has provided data
which may be used to formulate lipid diets rich in DHA in the context of an insufficient consumption of n-3 PUFA in Western countries.
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Numerous studies have demonstrated that n-3 PUFA, especially
EPA (20 : 5n-3) and DHA (22 : 6n-3), are associated with a reduced
risk of developing several pathologies such as cardiovascular(1),
neurodegenerative(2), inflammatory(3) diseases and cancer(4).
Indeed, EPA and DHA are directly implicated in lipid metabolism
by lowering triacylglycerolaemia (5) but they are also precursors of
eicosanoids with strong anti-inflammatory properties(3,6). Results
from the latest French epidemiological study(7) have shown that,
even if the consumption of total lipids was in line with the recom-
mendations (34 % of the total energy intake for 35–40% recom-
mended), EPA and DHA consumption was at least 32% lower
than the French guidelines (117 and 169mg/d, respectively, for rec-
ommendations of 250mg/d of each n-3 long-chain (LC) PUFA)(8,9).
In order to cover the n-3 LC PUFA physiological needs, increasing
EPAandDHA intakes represents amajor nutritional challenge.One
of the strategies consists in improving their bioavailability, without
changing the total lipid intake. Several studies have demonstrated
that lipid bioavailability depends on physicochemical factors of the
dietary intake(10–14). Indeed, nowadays, EPA and DHA are essen-
tially consumed as oily fish for food intake or as fish oil (mainly
TAG or ethyl esters) in food supplements. In the case of food
supplements, the interest for marine phospholipids (PL) has
recently increased. However, the limited data concerning the
impact of the molecular lipid species (TAG v. PL) of lipid intake
on the n-3 LC PUFA fate leads to conflicting results. On the one
hand, n-3 LC PUFA levels were increased in the liver and brain
of rats fed EPA and DHA in the form of PL compared with
TAG(15,16). On the other hand, accretion of DHA in rat liver, plasma
and kidney was significantly lower when it was provided as
PL(17,18). Human studies were even less conclusive. In a double-
blind, randomised, placebo-controlled, crossover study, a 4-week
consumption of 600 mg of n-3 LC PUFA in PL increased the n-3
LC PUFA levels in plasma and erythrocytes compared with the
TAG form(19). In contrast, no effect of the molecular species of
the dietary lipids (TAG v. PL) was observed on n-3 LC PUFA levels
in plasmaanderythrocytes after 28 consecutivedays of supplemen-
tation with 816 mg EPA per d and 522 mg DHA per d(20). These
contradictory results may account for different experimental
designs, especially different EPA:DHA ratios, and prevent accurate
comparison. Moreover, the impact of the molecular lipid species
form was often studied by using fish oil for TAG and krill oil for
PL. However, it is worth noting that krill oil only provides
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40–60%ofn-3 PUFA in the formof PL,while the remaining fraction
originates from TAG and NEFA(21,22). As a result, the role of PL as a
lipid carrier on n-3 LC PUFA metabolic fate is not clearly
established. To our knowledge, only one study provided n-3
PUFA only as TAG or as PL and showed a better lymphatic absorp-
tion of n-3 LC PUFA for rats fed PL v. TAG(23). However, PL were
structured in liposomeswhile TAGwere provided as fish oil in bulk
phase, so that the physical state of the two formulations was not
comparable.
Thereby, the objective of the present study is to provide data
on the digestibility and the intestinal absorption of n-3 LC PUFA
according to their molecular lipid species, only in the bulk oily
phase. Special attention was paid to ensure that the EPA:DHA
ratio in the dietary lipid sources remained the same in order to
ensure comparable results. n-3 LC PUFA esterified in TAG or
PLwere first subjected to an in vitro lipolysis in a titrimetricmodel.
Intestinal absorption of n-3 LC PUFA was studied in vivo in a rat
lymph duct fistula model. The lipid and fatty acid (FA) composi-
tions of the lymph were analysed. It is worth noting that in vivo
rodent models are considered as appropriate study models to
assess oral compound bioavailability. They are often used in sin-
gle-dose protocols or supplementation studies(11,12,14,23). Indeed,
similar physiological and physicochemical events, in particular
those implying lipolytic enzymes, are described in both rodents
and humans. Moreover, lymph analysis gives direct information
on intestinal bioavailability, in contrast to blood, where the lipid
composition may be contaminated by lipoproteins from liver
metabolism. Thus, rat studies provide useful data to better
understand the early stages of lipid digestion and investigate
the intestinal bioavailability of FA of interest.
Methods
Animals
Male Wistar rats (8 weeks old, body weight: 300–350 g) were
obtained from Elevage Janvier (Saint Genest sur l’Isle). All
experiments were carried out in compliance with the ethic
committee in Bordeaux and accepted by The French Ministry
under no. 2017031014448864. Rats were treated in accordance
with the European Communities Council Guidelines for the
Care and Use of Laboratory Animals (2010/63/EU). All experi-
ments conformed to the Guidelines for the Handling and
Training of Laboratory Animals. Rats were housed four per cage
(480 mm × 375 mm × 210 mm) for at least 7 d before the experi-
ment in a controlled environment, at constant temperature
(22 ± 1°C) and humidity (60 %) with free water and food access
and a 12 h light–12 h dark cycle.
Experimental design
At 24 h before surgery, rats were fed a fat-free diet (SAFE) with
free access to water. Each rat was placed under anaesthesia by
an intra-peritoneal injection of a ketamine–xylazine mixture
(100/10 mg/kg, respectively; Axience). A polyethylene catheter
(0·95 mm × 15 cm; Biotrol) was inserted into the main mesenteric
lymph duct as described by Bollman et al.(24) and Couëdelo
et al.(12). Immediately after surgery, rats were randomly assigned
to one of the three experimental groups (six rats/group), corre-
sponding to one of the three n-3 LC PUFA-enriched formulations
(TAGn-3, TAGn-3+PLveg, and TAGveg+PLn-3). A volume, equivalent
to 1 g of formulation, was orally administrated by gavage, provid-
ing, respectively, 8·6 and 22·3 mg of EPA and DHA per rat. Each
rat was then placed in an individual restraining cage (rat compart-
ment 228 mm × 89 mm), in a warm environment with freely
available water. After gavage, lymph was collected during 6 h
in a collection tube stored in ice. To prevent pain, rats received
an intra-peritoneal injection of buprenorphine (0·02 mg/kg;
Axience) 1 h before and 2 h after surgery. At 6 h post-intubation,
rats were euthanised by an intra-peritoneal injection of sodium
pentobarbital (Axience) and lidocaine (Ceva).
Lipid formulations
The lipid formulations were prepared at room temperature
under nitrogen in order to prevent PUFA oxidation. Three
marine formulations were designed to provide a similar amount
of FA, but differed by the chemical structure of lipids. More
precisely, EPA and DHA were exclusively esterified either on
TAG or on PL molecules (Table 1).
Marine PL were extracted from Lecimarin F50 (Novastell)
by solvent fractionation using cold acetone. Briefly, 1 ml of
chloroform–methanol (2:1, v/v) was added to 1 g of marine
lecithin and maintained at room temperature until complete
solubilisation. After addition of 20 ml of cold acetone (–20°C),
the sample was homogenised and then centrifuged (1050 g,
5 min, 4°C; Sorvall ST-40R, Thermo Fisher Scientific). The super-
natant, containing the neutral lipids, was removed and the pellet,
containing the polar lipids, was extracted twice with cold
acetone and stored at –20°C.
The formulation providing EPA and DHA only esterified in PL
(TAGveg+PLn-3) was prepared by solubilising marine PL
(13 wt.%) to a mixture of vegetable oils (flaxseed–copra–grape-
seed–palm–oleic sunflower oils; 1:6:6:30:57, by weight). The
formulation including EPA and DHA only on TAG (TAGn-3)
was obtained by blending two fish oils (Omegavie 1812 TG
and Omegavie Tuna oil 25 % DHA; 1:10, w/w; Polaris) to 11
wt.% of blended vegetable oils (flaxseed–copra–grapeseed–
palm–oleic sunflower oils; 1:6:6:31:56, by weight). In order to
distinguish the role of PL, acting either as emulsifier or as FA
carrier, a third formulation (TAGn-3+PLveg) was prepared includ-
ing vegetable PL (without n-3 LC PUFA contribution). More
precisely, 11 wt.% of the marine oil and 10 wt.% of soya lecithin
(Nat&Form) were added to a mixture of vegetable oils (copra,
palm and oleic sunflower oils; 6:30:63, by weight).
Phospholipid classes of marine polar lipid extract and of soya
lecithin were characterised by proton NMR (1H NMR) according
to Cansell et al.(25) (Table 1). The glyceride structure of the
marine oil mixture and of the marine PL was enzymatically
determined according to the methods described below. In
the marine TAG (oil mixture), EPA was mainly esterified in
the sn-1/3 positions of marine TAG (26 % in the sn-2 position),
whereas DHA was mainly located in the sn-2 position (50 %).
In marine PL, both EPA and DHA were essentially distributed
in the sn-2 position (>74 %) (see online Supplementary
material S1).
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The total lipids were extracted from the lymph according to the
procedure described by Folch et al.(26). PL and TAG
fractions from the lipid extract were separated by TLC (glass plates
20 × 20 cm pre-coated with silica gel 60H) using a solvent mixture
composed of hexane–diethyl ether–formic acid (75:35:1, by vol.).
After vaporisation of 2,7-dichlorofluorescein (Sigma-Aldrich) and
visualisation under UV light, the spots corresponding to PL and
TAG were extracted from the silica gel by the addition of 2·5 ml
of chloroform–methanol (2:1, v/v). After homogenisation and cen-
trifugationof the scraped fractions (1050g, 5min, 20°C), the organic
phase containing lipids was collected. The extraction step was
repeated by the addition of distilled water (100 μl) and
chloroform–methanol 2 ml (2:1, v/v) to the silica gel phase. Lipid
extraction from the silica gel was ended by the addition of 2 ml
of methanol to the silica gel phase, homogenisation and centrifuga-
tion. Theoverall organic phaseswerepooled anddried under nitro-
gen. Finally, 2,7-dichlorofluorescein was removed using 0·4ml of a
KCl solution (0·8% in distilled water, w/v) and 2 ml of chloroform–
methanol (2:1, v/v). The organic phase was washed twice by the
addition of 0·8 ml of a mixture of chloroform–methanol–KCl
0·8% in distilled water (15:240:235, by vol.). Samples were stored
at –20°C until analysis.
The FA composition of the lipid formulations, the samples from
the in vitro lipolysis experiments and those collected from the
lymph, that is, total lipids, TAG and PL fractions, were submitted
to the trans-methylation procedure adapted from Castro-
Gomez(27,28). The resulting fatty acid methyl esters were analysed
by GC analysis (TRACE GC, Thermo Fisher Scientific) equipped
with a flame ionisation detector and a split injector. A fused-silica
capillary column (BPX 70, 60 m × 0·25 mm internal diameter,
0·25 μm film; SGE) was used with hydrogen as a carrier gas (inlet
pressure: 120 kPa). The split ratio was 1:33. The column temper-
ature program was as follows: from 160°C, the temperature
increased to 180°C at 1·3°C/min and was maintained for 65 min
before increasing at 25°C/min to 230°C, temperature that was
maintained for 15min. The injector and detector were maintained
at 250°C and 280°C, respectively. Gas chromatographic peaks
were integrated using Chromquest software (Thermofinnigan).
Fatty acids were quantified using an internal standard (1 mg/ml
in chloroform–methanol (2:1, v/v)) added at 10% of the lipid
weight before the trans-methylation procedure. NEFA 17 : 0
(heptadecanoic acid; Nu-Chek Prep) was used as an internal
standard for the in vitro lipolysis study. TAG 17 : 0 (1,2,3-
triheptadecanoyl-sn-glycerol; Nu-Chek Prep) and PC 17 : 0 (1,2-
diheptadecanoyl-sn-glycero-3-phosphatidylcholine; Avanti Polar
Lipids) were used for TAG and PL quantification of the lymph
samples, respectively.
The proportion of FA esterified in the sn-2 position of lymph
TAG was determined using the regiospecificity of lipase. Lymph
TAG (3mg) weremixedwith 1ml of lipase B Candida antartica
(>2000 U/g; 1 U= 1 μEq FA/h; Sigma-Aldrich) in ethanol
solution (4 mg/ml, w/v) and placed under stirring, at 30°C for
3 h. Lipids were extracted six times by 10 ml of diethyl ether.
Hydrolysis products were separated by TLC using a solvent
mixture composed of hexane–diethyl ether–acetic acid
(70:30:1, by vol.). After vaporisation of 2,7-dichlorofluorescein
and visualisation under UV light, the spots corresponding to
the 2-monoacylglycerols (2-MG) were scraped off and trans-
ferred into a glass tube for their trans-methylation. The propor-
tion of FA esterified in the sn-2 position of TAGwas calculated by
considering the proportions of each FA from 2-MG compared
with those from the three positions of the TAG, with the
following equation:
% FA in sn-2 TAG ¼ ð% FA in 2-MG 100Þ=ð% FA in TAG 3Þ:
The glyceride structure of lymph PL was achieved by phos-
pholipase A2 (PLA2) hydrolysis according to the Wolff et al.(29)
method, using PLA2 from bee venom (600–2400 U/g; 1U= 1
μEq FA/h; Sigma-Aldrich). Briefly, 150 μl of a PLA2 solution
(1 mg/ml; 3 mM CaCl2) was added to 2 mg of extracted lymph
PL and 1 ml of diethyl ether. Samples were incubated under
stirring, at 30°C for 1 h. The reaction was stopped by solvent
evaporation under nitrogen. Hydrolysis products were separated
byTLCusing a solventmixtureof chloroform–methanol–distillated
water (65:25:4, by vol.). NEFA were scraped off and transferred
into a glass tube for methylation. The proportion of FA esterified
in the sn-2 position of PL was calculated by considering the
proportions of each FA released as NEFA compared with those
from the two positions of the PL, with the following equation:
% FA in sn-2 PL ¼ ð% FA in NEFA 100Þ=ð% FA in PL 2Þ:
In vitro intestinal lipolysis of lipid formulations
The enzymatic lipolysis of the lipid formulations was assessed
using an in vitro digestion model that mimics the physiological
Table 1. Fatty acid and phospholipid (PL) compositions of the three
experimental lipid formulations
TAGn-3 TAGn-3+PLveg TAGveg+PLn-3
Fatty acid composition (g/100 g total fatty acids)
Σ SFA 32·6 31·4 31·0
16 : 0 15·9 15·4 15·4
18 : 0 3·5 3·4 3·3
Σ MUFA 55·0 57·0 56·7
18 : 1n-9 52·8 54·6 55·1
Σ PUFA 12·4 11·6 12·3
Σ n-6 PUFA 8·6 7·7 8·7
18 : 2n-6 8·2 7·2 8·4
20 : 4n-6 0·2 0·2 0·0
Σ n-3 PUFA 3·8 3·9 3·4
18 : 3n-3 0·7 0·4 0·7
20 : 5n-3 0·8 0·9 0·7
22 : 6n-3 2·0 2·2 1·9
n-6:n-3 2·3 2·0 2·6





Phosphatidic acid 4·0 1·2
Sphingomyelin – 2·9
Lysophosphatidylcholine – 9·2
LC, long-chain; TAGn-3, oil phase with n-3 LC PUFA esterified in TAG; TAGn-3+PLveg,
oil and soya lecithin mix with n-3 LC PUFA esterified in TAG; TAGveg+PLn-3, oil and
marine PL mix with n-3 LC PUFA esterified in PL.
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conditions of the intestinal lumen according to Carrière et al.(30)
and Minekus et al.(31) with slight modifications. The lipolysis was
initiated by 5ml of a 25 % lipid emulsion stabilised by 1·4 % (w/v)
of methyl cellulose (Sigma-Aldrich) and dispersed in 15 ml
of an assay solution containing 0·6 % (w/v) of methyl cellulose,
150 mM NaCl (Thermo Fisher Scientific), 1·4 mM CaCl2 (Sigma-
Aldrich) and 20 mM sodium deoxycholate (Sigma-Aldrich).
This mixture was stirred in a temperature-controlled reaction
vessel at 37°C and the pH was adjusted to 7·5. The lipolysis
was initiated by adding 1 ml of porcine pancreas extract solution
(6·7 mg/ml in distilled water, pH 7·5; Sigma-Aldrich) to the reac-
tion vessel. The pHwas kept constant at 7·5 for 60 min with 0·1 M
NaOH (Chem-Lab) automatically controlled by a pH-stat device
(pHstat Titrando, Metler Toledo). Samples (0·5 ml) were col-
lected at times ranging from 0 to 60 min for lipid extraction
and analysis. Lipid extraction was immediately performed
by mixing each sample vigorously (0·5 ml) with 200 μl HCl
(0·1 M; Thermo Fisher Scientific) and 5 ml chloroform–methanol
(2:1, v/v) in a glass tube. After phase separation, the upper aque-
ous phasewas removed and the lower phase containing the total
lipids was dried under nitrogen, dissolved in 3 ml chloroform–
methanol (2:1, v/v), and stored at –20°C until analysis. NEFA,
from TAG and PL lipolysis, were isolated from other lipid frac-
tions by TLC (glass plates 20 × 20 cm pre-coated with silica
gel 60H (Merck KGaA)) using a solvent mixture composed of
hexane–diethyl ether–acetic acid (80:20:1, by vol.). Spots were
visualised under UV light after vaporisation of 2,7-dichlorofluores-
cein in ethanol solution (0·2%, w/v). NEFA were scraped off and
transferred into a glass tube for methylation and GC analysis. At
each time point of the kinetics (0, 5, 10, 15, 30 and 60 min), the
hydrolysis level (% NEFA/total FA) was calculated. A deprived
n-3 LC PUFA formulation composed of 10 wt.% of soya lecithin
dissolved in a vegetable oil mixture (copra–palm–oleic sunflower
oil; 6:30:63, by weight; TAGveg+PLveg) was also assessed as a
control (see online Supplementary material S2). Lipolysis experi-
ments were performed in triplicate, for each formulation, that is,
TAGn-3, TAGn-3+PLveg and TAGveg+PLn-3.
Characterisation of lymph chylomicrons
The size of the lymph chylomicrons (CM)wasmeasured for each
rat group by dynamic light scattering using VascoTM (Cordouan
Technologies). Lymph samples were firstly diluted in NaCl
solution in water (0·9 %, w/v). Experiments were performed
considering a water refractive index of 1·331 and a viscosity of
0·888 cP. The real part and the imaginary part of particles were
fixed at 1·47 and 0·01, respectively.
Statistical analysis
Data were expressed as means and standard deviations.
Intergroup comparisons were made on the basis of their respec-
tive mean. For the in vitro lipolysis experiment (n 3), multiple
comparisons were analysed using a two-way ANOVA with
two independent factors (lipid formulation and time of lipolysis)
followed by a Bonferroni post hoc test, using GraphPad Prism
version 7. Data issued from the in vivo intestinal absorption
experiment (n 6) were compared by a one-way ANOVA test
followed by a Tukey post hoc test, using R version 3.5.1
(Rcommander package). P values lower than 0·05 were consid-
ered to be statistically significant.
Results
In vitro digestion of n-3 long-chain PUFA is modulated by
their molecular lipid species of intake
Marine formulations (TAGn-3, TAGn-3+PLveg, TAGveg+PLn-3) were
subjected to in vitro lipolysis in a one-step static digestion model,
with a focus on the duodenal lipolysis (Fig. 1). Results revealed that
all lipid formulations were well hydrolysed during the time course
of the lipolysis but to a different extent according to the formulation
used (Ptime<0·001; Plipids=0·05 and Pinteraction<0·001; two-way
ANOVA test). At the end of the lipolysis kinetics (60 min), the pres-
ence of soya lecithin in the marine formulation (TAGn-3+PLveg)
tended to inhibit the total lipolysis comparedwith TAGn-3 (lipolysis
level of 21·3 (SD 4·7)% and 14·5 (SD 1·5)%, for TAGn-3 and
TAGn-3+PLveg, respectively). The lipolysis of TAGn-3+PLveg formu-
lationwas decreased by 47%when comparedwith the formulation
free of n-3 LC PUFA (lipolysis level of 14·5 (SD 1·5)% and 27·3
(SD 1·9)% for TAGn-3+PLveg and TAGveg+PLveg, respectively;
P<0·05). When n-3 LC PUFA were esterified in marine PL
(TAGveg+PLn-3), the lipolysis seemed to be slower at the beginning
of the kinetics compared with the control curve (TAGveg+PLveg);
however at 60min, the lipolysis levelswere not statistically different
(21·5 (SD 4·3)% and 27·3 (SD 1·9) % for TAGveg+PLn-3 and
TAGveg+PLveg, respectively).
Influence of the molecular lipid species of the dietary
lipids on the intestinal absorption of n-3 long-chain PUFA
At 6 h after lipid ingestion, no adverse effect was observed
consecutive to lipid formulation intubation. The total FA concen-
tration in the rat lymph was similar for the three marine formu-
lations (Table 2). The proportions of EPA andDHA in lymph total
FA did not show statistical differences between all groups.
Lymph TAG and PL were separated and their FA compositions
were analysed separately (Table 3). The relative proportions
of lymph TAG and PL were similar regardless of the molecular
n-3 LC PUFA carrier (P>0·05). Thereby, TAG was the major lipid
fraction (71 % of total FA) while PL only represented 7 % of total
FA. Lymph TAG presented a similar FA profile between the three
groups (P>0·05). SFA and MUFA were the two major FA classes,
and PUFA were mainly represented by n-6 PUFA. Considering
n-3 PUFA, EPA and DHA levels in lymph TAG were similar in
the three groups. In lymph PL, the incorporation of n-3 LC
PUFA and specifically EPA was quite low. DHA levels tended
to be higher in the TAGveg+PLn-3 than in TAGn-3 and
TAGn-3+PLveg (P=0·10). The proportions of the main FA
esterified in the sn-2 position of lymph lipids were defined
(Table 4). We noted that SFA, MUFA and PUFA were equally
distributed in the three positions of lymph TAG for all groups.
In lymph PL, SFA were mostly esterified in the sn-1 position
and PUFA in the sn-2, irrespective of the groups. Considering
n-3 LC PUFA, EPA and DHA were mainly located in the sn-2
position of lymph PL regardless the molecular FA carrier
(TAG v. PL). DHA was equally esterified in the three
positions of lymph TAG when provided as marine TAG
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(TAGn-3 and TAGn-3+PLveg), whereas it wasmainly located in the
sn-1/3 positions when ingested as marine PL (TAGveg+PLn-3;
P<0·001). More precisely, the intake of marine PL decreased
by 46 % the proportion of DHA esterified in the sn-2 position
of lymph TAG. However, EPA was mainly inserted in the
sn-1/3 positions of lymph TAG in all groups.
Characterisation of lymph chylomicrons
Lymph CMwere analysed in terms of particle size. Data revealed
that the mean diameter of CM were comparable between the
three groups (223 (SD 28), 248 (SD 46) and 227 (SD 47) nm for
TAGn-3, TAGn-3+PLveg and TAGveg+PLn-3, respectively).
Discussion
The present study aims at evaluating the impact of the molecular
lipid species of dietary n-3 LC PUFA on (i) their in vitro digest-
ibility and (ii) their intestinal bioavailability, in rats fed marine
TAGor PL. Only few studies tried to couple in vitro lipid hydroly-
sis with in vivo absorption and they dealt with plant lipids(11,12).
A recent study used marine lipids(32). However, the formulations
did not have a similar EPA:DHA ratio and did not allow compari-
son of PL as n-3 carrier or as emulsifier. In our work, lipid for-
mulations were designed to provide a similar amount of EPA
andDHA, esterified exclusively either in TAG or in PLmolecules.
Because PL display surfactant properties that may influence lipid
digestibility and absorption, a formulation containing soya leci-
thin instead of marine PL (TAGn-3+PLveg) was also assessed.
Results showed that even if the in vitro lipolysis level was depen-
dent on the type of the formulation used, EPA and DHA were
similarly absorbed, in vivo, regardless of the lipid carrier.
However, they were differently distributed in lymph lipid frac-
tions. Specifically, when provided as marine PL, n-3 LC PUFA
tended to be better incorporated in lymph PL andDHAwasmore
externalised in the glycerol backbone of lymph TAG. To our
knowledge, this is the first study analysing the molecular struc-
ture of lymph lipid fractions using marine TAG and PL as dietary
n-3 LC PUFA carriers.
Gastro-intestinal digestion can be considered as a limiting
step of bioavailability. This is because dietary lipids first have
to be hydrolysed in the gastro-intestinal tract, before being
absorbed by the intestinal brush border. In our study, we did
not perform a gastric phase before the duodenal phase, which
could be a limitation. However (1) duodenal lipolysis represents
nearly 70 % of total lipolysis(33) and (2) the efficiency of the intes-
tinal lipolysis is not called into question by the gastric phase. Our
data confirmed that lipolysis extent depended on the affinity of
pancreatic lipase towards the lipid species. The presence of n-3
LC PUFA esterified in marine TAG (TAGn-3+PLveg v.
TAGveg+PLveg) dramatically impaired the lipolysis rate, due to
the molecular structure of EPA and DHA which led to a steric
hindrance effect in in vitro studies(34,35). In agreement with
other studies(12,36), we observed an inhibitory effect of soya PL
(TAGn-3 v. TAGn-3+PLveg). This could be interpreted as an
impediment of the binding of pancreatic lipase/co-lipase at
the oil–water interface, decreasing TAG availability for hydroly-
sis(37,38). Moreover, the PL nature influenced the lipid hydrolysis
level (TAGveg+PLveg v. TAGveg+PLn−3). In our experiment, the
porcine pancreas extract contained PLA2. It is well known that
PLA2 activity is modulated by the nature of the polar head group
of PL and to a lesser extent by the FA nature, that is, chain length
or unsaturation degree(39,40). Several studies using lipo-
somes(41,42) and emulsion droplets(43) showed that PLA2 would
preferentially bond to anionic PL rather than zwitterionic PL.
Thus, in our study, a part of the decreased lipolysis observed
with TAGveg+PLn−3 formulation could be attributed to the PL
composition (5 % of anionic PL in PLn-3 v. 39 % in PLveg).
The products generated by the lipid hydrolysis (NEFA, 2-MG,
and lysophospholipids) are micellised by biliary salts before
being absorbed through the intestinal brush border. In the enter-
ocytes, the lipolysis products are re-synthesised in TAG and PL,
compacted into CM to be released into the lymph compartment
before reaching the bloodstream. In our experiment, the CM
diameter was similar, whatever the molecular carriers used,
suggesting that the structural properties of CM were impacted
neither by the presence of PL in the formulation nor by the
molecular n-3 LC PUFA carrier used, nor by the variations of
lipolysis rates observed in vitro. This finding is in accordance
with a previous study demonstrating that the lipid composition
of CM did not differ in rats fed fish oil or marine PL(23).
In all experimental groups, the FA quantification and FA profile
of total lymph lipids were similar, suggesting that, under our test
conditions, the digestion and the intestinal absorption of n-3 LC
PUFA were not modulated by the molecular n-3 LC PUFA carrier
(TAGn-3 v. PLn-3). Moreover, lymph lipids were mainly composed
of PL and TAG and the incorporation of EPA and DHA in lymph
lipid fractions occurred independently of the molecular lipid
species used (i.e. TAG, PL, lysophospholipids, NEFA)(23,42–44).
Indeed, the FA profile of lymph TAG revealed similar n-3 PUFA
levels between the three groups, suggesting that EPA and DHA
were incorporated in lymph TAG regardless of the molecular FA
carrier.However, in lymphPL,DHA levels tended to increasewhen




























Fig. 1. Effect of lipid formulationon lipolysis levels using an invitrodigestionmodel.
TAGn-3 (•), TAGn-3+PLveg (▴), TAGVeg+PLn-3 (□) and TAGveg+PLveg (Δ). Lipolysis
levels are expressed as % NEFA v. total acyl chains in the residual TAG,
diacylglycerols, monoacylglycerols and NEFA. Values are means with standard
deviations (n 3). a,b Values with unlike letters for the same time are significantly
different (P<0·05; two-way ANOVA followed by Bonferroni post hoc test).
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form of intake (TAGn-3 and TAGn-3+PLveg). These data agreewith a
previous study where the proportions of n-3 LC PUFA in CM-PL
were increased with marine PL compared with fish oil(23,32). It
has been suggested that FA absorption could be lower in anaes-
thetised rats than in conscious animals. Nonetheless, the relative
distributionofDHA in lymph lipid fractions is expected to be similar
regardless of the consciousness state of the rats(44).
The analysis of the glyceride structure of TAG clearly showed
that the molecular n-3 LC PUFA carrier influenced the mecha-
nisms involved in the re-synthesis of lymph lipids. In the enter-
ocyte, lymph TAG are mainly synthesised by the 2-MG pathway.
We found that marine TAG intake (TAGn-3 and TAGn-3+PLveg)
led to an equimolar distribution of DHA in the three positions
(33 % of each) of lymph TAG, whereas the DHA provided
was 56 % esterified in the sn-2 position in marine TAG formu-
lation. This showed that the sn-2 position of the dietary TAG
was not fully conserved in lymph TAG. A similar conclusion
was drawn when structured TAG rich in α-linolenic acid
(18 : 3n-3) were used, that is, only 50 % of α-linolenic acid
located in the sn-2 position of dietary TAGwere recovered at this
position in rat lymph TAG(45). This was interpreted as either (i) an
isomerisation of 2-MG into 1-MG prior to the lipolytic activity of
pancreatic lipase(46) or (ii) a hydrolysis of the absorbed
2-MG by an intestinal lipase in the enterocyte(47). This suggested
Table 2. Effect of the molecular carrier form of n-3 long-chain (LC) PUFA on fatty acid composition (g/100 g of total fatty acids) of total lipids of lymph of rats*,
6 h after intubation
(Mean values and standard deviations)
TAGn-3 TAGn-3+PLveg TAGveg+PLn-3
Mean SD Mean SD Mean SD
Σ SFA 27·4a 1·5 26·4a 1·0 26·3a 1·6
16 : 0 17·8a 1·0 18·5a 0·7 17·9a 1·0
18 : 0 4·8a 0·4 5·1a 0·8 5·0a 0·3
Σ MUFA 49·9a 3·5 52·4a 3·1 52·5a 3·8
18 : 1n-9 45·5a 4·6 48·0a 3·5 48·8a 4·3
Σ PUFA 22·8a 2·8 21·2a 2·1 21·3a 3·0
Σ n-6 PUFA 18·8a 2·6 17·3a 2·0 17·5a 2·5
18 : 2n-6 14·2a 2·0 12·7a 1·3 13·5a 2·0
20 : 4n-6 3·8a 0·7 3·8a 0·9 3·5a 0·7
Σ n-3 PUFA 3·9a 0·2 3·8a 0·1 3·7a 0·9
18 : 3n-3 1·1a 0·1 0·7b 0·1 1·0a 0·2
20 : 5n-3 0·5a 0·0 0·6a 0·0 0·5a 0·2
22 : 6n-3 1·8a 0·1 2·0a 0·2 1·9a 0·7
n-6:n-3 4·8a 0·5 4·5a 0·5 5·0a 1·2
Total fatty acids (mg/ml) 13·9a 4·0 15·5a 9·1 15·3a 5·6
PL, phospholipids; TAGn-3, oil phasewith n-3 LCPUFAesterified in TAG; TAGn-3+PLveg, oil and soya lecithinmix with n-3 LCPUFAesterified in TAG; TAGveg+PLn-3, oil andmarinePL
mix with n-3 LC PUFA esterified in PL.
a,b Mean values within a row with unlike superscript letters are significantly different (P<0·05; ANOVA followed by Tukey’s post hoc test).
* n 6.
Table 3. Effect of themolecular carrier form of n-3 long-chain (LC) PUFA on fatty acid composition (g/100 g of total fatty acids) of TAG and phospholipids (PL)
of lymph of rats*, 6 h after intubation
(Mean values and standard deviations)
Lymph TAG Lymph PL
TAGn-3 TAGn-3+PLveg TAGveg+PLn-3 TAGn-3 TAGn-3+PLveg TAGveg+PLn-3
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Σ SFA 26·3a 2·1 25·9a 1·9 25·7a 1·9 39·5a 1·1 38·4a 1·2 39·2a 1·3
16 : 0 17·8a 1·0 18·4a 0·9 17·7a 1·0 20·4a 1·2 18·8b 0·8 19·9a,b 1·2
18 : 0 4·0a 0·4 4·1a 0·5 4·0a 0·3 17·6a 1·1 18·3a 1·3 17·8a 1·1
Σ MUFA 53·6a 2·9 55·7a 3·4 55·9a 3·8 13·7a 2·6 13·4a 1·9 14·5a 3·2
18 : 1n-9 49·0a 4·1 51·3a 3·8 52·3a 4·0 9·1a 2·8 8·7a 2·0 8·7a 3·5
Σ PUFA 20·1a 2·8 18·4a 1·7 18·6a 2·1 46·9a 2·0 48·2a 2·5 46·3a 2·4
Σ n-6 PUFA 16·2a 2·4 14·6a 1·7 14·9a 1·6 43·7a 2·2 44·8a 2·4 42·3a 2·1
18 : 2n-6 13·2a 2·1 11·7a 1·4 12·5a 1·5 23·9a 2·0 24·6a 1·7 24·2a 2·3
20 : 4n-6 2·3a 0·4 2·3a 0·6 2·0a 0·4 18·2a 1·5 18·8a 2·3 16·9a 1·9
Σ n-3 PUFA 3·8a 0·4 3·7a 0·1 3·5a 0·9 3·1a 0·2 3·3a 0·2 3·9a 1·1
18 : 3n-3 1·1a 0·2 0·7b 0·1 1·0a 0·1 0·3a 0·0 0·3b 0·0 0·3a 0·0
20 : 5n-3 0·5a 0·1 0·6a 0·0 0·4 a 0·1 0·8a 0·1 1·0a 0·2 1·1a 0·4
22 : 6n-3 1·7a 0·2 1·9a 0·2 1·8a 0·7 1·6a 0·2 1·7a 0·3 2·1a 0·6
n-6:n-3 4·2a 0·2 4·0a 0·5 4·5a 1·1 14·2a 1·7 13·5a 0·3 11·5a 3·4
Total fatty acids (mg/ml) 9·1a 2·5 12·2a 7·7 10·4a 4·9 1·2a 0·4 1·1a 0·6 1·1a 0·5
TAGn-3, oil phase with n-3 LC PUFA esterified in TAG; TAGn-3+PLveg, oil and soya lecithin mix with n-3 LC PUFA esterified in TAG; TAGveg+PLn-3, oil and marine PL mix with n-3 LC
PUFA esterified in PL.
a,b Mean values within a row with unlike superscript letters are significantly different (P<0·05; ANOVA followed by Tukey’s post hoc test).
* n 6.
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that new metabolic pathways could take place as soon as the
concentration of a lipid species varied greatly, thus ensuring a
‘homeostatic’ state. On the contrary, in marine PL, DHA was
exclusively (>74 %) esterified in the sn-2 position of the glycerol
backbone. After PL digestion, DHA was mainly released as
NEFA, due to a predominant activity of PLA2, specific of the
sn-2 position of PL(48). Thus, the presence of DHA in the sn-2
position of lymph TAG suggested that the glycerol-3-phosphate
pathway was involved for the de novo TAG synthesis using un-
esterified DHA. Indeed, the glycerol-3-phosphate pathway
could account for at least 15 % of lymph TAG synthesis.
Nevertheless, the major pathway for re-synthesis of lymph
TAG seemed to be the 2-MG pathway, leading to the incorpora-
tion of a large part of free DHA on the 2-MG backbone. In this
way, TAGveg+PLn-3 ensured a DHA enrichment in the sn-1/3
positions of lymph TAG compared with the marine TAG groups
(TAGn-3 and TAGn-3+PLveg). The analysis of the glyceride struc-
ture of PL showed the same n-3 LC PUFA repartition in the three
dietary groups. Lymph PL mainly originate from the re-acylation
of 1-lysophospholipids; this suggested that, irrespective of the
amount of free DHA in the enterocyte, the composition of lymph
PL is highly regulated with an incorporation mainly in the sn-2
position.
These mechanisms are confirmed with the metabolic fate of
EPA. Indeed, EPA was less esterified in the sn-2 position of
lymph TAG when provided as marine PL than as marine TAG.
Nevertheless, since EPA was mainly distributed in the sn-1/3
positions of marine TAG and in sn-2 position of marine PL,
it was essentially absorbed as NEFA after gastro-intestinal
hydrolysis. Free EPA was then incorporated either in the sn-1/3
positions of lymph TAG or in the sn-2 position of lymph PL.
In conclusion, the present study was undertaken to analyse
the impact of different molecular carriers of n-3 LC PUFA that
could increase their bioavailability, based on in vivo data. Our
results showed that dietary PL from vegetable or animal sources
added to the oily formulations, at the ratio of 10 %, did not
increase lipid absorption. Although lipolysis differed according
to the composition of the formulation, it seemed that themolecu-
lar carrier did not greatly modify the intestinal absorption of n-3
LC PUFA. In contrast, the nature of the dietary lipidsmightmodu-
late FA incorporation and distribution in lymph lipid fractions.
However, it would be interesting to complete the present study
with the analysis of gene and protein expressions as well as with
the activities of some enzymes implied in the intracellular lipid
metabolism pathways to consolidate our data. The fact that,
when provided as marine PL, DHA was better incorporated in
lymph PL and was externalised in lymph TAGmay further affect
its metabolic fate and tissue accretion. Indeed, previous reports
indicated that using PL as n-3 LC PUFA carriers can be more
efficient than TAG regarding the metabolisation and hypoadipo-
genic effect of EPA and DHA(10,15,16,49–51).
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Table 4. Effect of the molecular carrier form of n-3 long-chain (LC) PUFA on fatty acid distribution (% esterified in the internal sn-2 position) in TAG and
phospholipids (PL) of lymph of rats*, 6 h after intubation
(Mean values and standard deviations)
Lymph TAG Lymph PL
TAGn-3 TAGn-3+PLveg TAGveg+PLn-3 TAGn-3 TAGn-3+PLveg TAGveg+PLn-3
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Σ SFA 31·6 9·6 27·2a 1·4 28·8a 3·4 20·6a 8·3 17·6a 10·1 13·7a 3·6
16 : 0 29·2a 6·8 29·1a 1·0 29·5a 2·1 22·3a 8·6 20·0a 11·1 14·7a 3·8
18 : 0 28·6a 5·8 22·7a 1·3 23·2a 3·7 17·4a 8·4 14·7a 9·6 10·9a 3·4
Σ MUFA 32·2a 3·3 34·0a 0·9 33·5a 1·2 38·2a 9·7 39·0a 4·9 35·7a 8·3
18 : 1n-9 33·2a 3·4 35·0a 0·6 34·1a 0·9 43·1a 7·6 46·4a 4·5 46·8a 8·4
Σ PUFA 39·0a 4·6 39·9a 1·6 39·2a 1·5 78·6a 8·5 79·1a 9·2 85·7a 5·7
Σ n-6 PUFA 41·0a 4·4 42·0a 1·7 43·1a 0·9 79·3a 9·3 79·6a 9·1 86·7a 6·4
18 : 2n-6 44·3a 5·0 43·9a 2·0 44·9a 1·4 80·3a 5·5 79·3a 7·7 87·4a 7·4
20 : 4n-6 28·6a 4·4 34·3b 2·3 32·1a,b 1·1 79·8a 6·3 81·8a 11·6 87·6a 6·4
Σ n-3 PUFA 30·3a 6·0 32·3a 1·5 23·9b 2·4 73·1a 11·1 73·4a 12·0 77·0a 13·7
18 : 3n-3 31·2a 4·0 27·9a 1·4 31·4a 1·1 59·9a,b 6·1 53·1a 5·1 63·5b 7·2
20 : 5n-3 18·2a,b 3·5 19·4a 2·0 14·5b 3·6 75·1a 7·3 83·5a 19·1 85·6a 11·7
22 : 6n-3 30·4a 8·5 33·7a 1·7 17·3b 1·5 72·1a 5·1 73·7a 10·6 78·4a 19·7
TAGn-3, oil phase with n-3 LC PUFA esterified in TAG; TAGn-3+PLveg, oil and soya lecithin mix with n-3 LC PUFA esterified in TAG; TAGveg+PLn-3, oil and marine PL mix with n-3 LC
PUFA esterified in PL.
a,b Mean values within a row with unlike superscript letters are significantly different (P<0·05; ANOVA followed by Tukey’s post hoc test).
* n 6.
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